Hormonal
Higher erythrocyte trans fatty acid content is significantly associated with an elevated risk of coronary heart disease (CHD), with individuals in the highest quartile having a relative risk of 3.3 compared to the lowest quartile after adjusting for cardiovascular risk factors and other fatty acids.
High levels of trans fats in your blood cells are a strong predictor of heart disease risk. This risk persists even after accounting for other lifestyle factors like smoking, weight, and exercise. To mitigate this risk, minimize intake of partially hydrogenated oils found in many processed foods, as these directly elevate your trans fat biomarkers and negatively impact your cholesterol profile.
After adjustment for age, smoking status, and other dietary and lifestyle cardiovascular risk factors, higher total trans fatty acid content in erythrocytes was associated with an elevated risk of CHD. The multivariable relative risks (95% confidence intervals) of CHD from the lowest to highest quartiles of total trans fatty acid content in erythrocytes were 1.0 (reference), 1.6 (0.7 to 3.6), 1.6 (0.7 to 3.4), and 3.3 (1.5 to 7.2) (P for trend <0.01).
Why this rating
Nested case-control design within a large prospective cohort (Nurses' Health Study) with rigorous biomarker analysis and adjustment for confounders, though observational nature prevents causal proof.
Source
A Prospective Study of <i>Trans</i> Fatty Acids in Erythrocytes and Risk of Coronary Heart Disease
Qi Sun et al. · Circulation · 2007
DOI 10.1161/circulationaha.106.679985
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →